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addition to that induced by antigen.
Second, the antigen was created by
chemical conjugation of HEL with
GFP, which created a range of mul-
timeric forms. It is not clear whether
aspects of B cell activation or anti-
gen distribution were dependent on
or related to a particular degree
of multimerization and additionally
whether some of the injected antigen
was in a particulate rather than soluble
form.
Do the data of Pape et al. [2007] re-
fute the previous findings? Absolutely
not, but they reveal—again—the ex-
traordinary diversity of the immune
system such that it is able to deal
with challenges that arrive via multiple
routes and in multiple forms. Antigen
may arrive for presentation both free
and as DC bound. It is possible, how-
ever, that B cells are preferentially
stimulated by the former route and T
cells by the latter. Optimizing the mix
of antigen types could maximize the
immune responses induced.
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The role that monocyte-derived dendritic cells play in vivo remains enigmatic. Leo´n et al. (2007) now
show that these cells develop ‘‘on demand’’ at a site of Leishmania infection to promote a life-saving
T helper 1 immune response.For many immunologists, the term
‘‘dendritic cell’’ (DC) evokes one type
of immunosurveilling leukocyte, dis-
tributed throughout the body, ready to
respond to pathogens that breach the
physical barriers that protect us from
infection. To carry out this function,
DCs possess highly effective mecha-
nisms to detect and capture patho-
gens at the site of infection. Such an
encounter triggers migration of DCs to
the T cell areas of the spleen and lymph
nodes, where DCs present pathogen
antigens to T cells to initiate immunity
(Wilson and Villadangos, 2005). In con-
trast to this ‘‘one-size-fits-all’’ descrip-
tion of the DC life cycle, we now know
that DCs are heterogeneous and com-
prise distinct subtypes that vary in he-
matopoietic origin, life cycle, and func-
tional capabilities (Shortman and Naik,
2007; Villadangos and Heath, 2005).
How the different components of this390 Immunity 26, April 2007 ª2007 Elsev‘‘DC network’’ interact with each other
and which functional niches they oc-
cupy in the immune system are impor-
tant and exciting questions. In this is-
sue of Immunity, Leo´n et al. (2007)
contribute an important piece of the
DC puzzle by describing the function
of monocyte-derived DCs (mo-DCs) in
immunity against skin infection by the
parasite Leishmania major (L. major)
(Leo´n et al., 2007). Their results reveal
an important role for this DC type in
mediating an effective immune re-
sponse at a time when other DC sub-
setsmay not be capable of copingwith
the infection.
Mo-DCs represent the best-studied
type of human DCs because they can
be generated in large numbers from
blood precursors. Likewise, DCs de-
rived from bone marrow, and that
probably correspond to mo-DCs as
well, are the most common type ofier Inc.mouse DC examined. However, most
of the studies on these DC types have
been carried out in vitro, and only re-
cently has their in vivo function started
to be elucidated. This may appear par-
adoxical: Haven’t DCs extracted from
the lymphoid organs of mice (and, oc-
casionally, humans) been studied for
decades? The problem is that the
DCs contained in the lymphoid organs
in the steady state (in the absence of
overt infections) are not mo-DCs but
are other DC types that constitutively
migrate from the tissues (‘‘migratory’’
DC) or that spend their entire life cycle
in the lymphoid organs (‘‘resident’’
DC) (Figure 1). Under these steady-
state conditions, mo-DCs are not de-
tectable in the lymphoid organs (Gra-
nelli-Piperno et al., 2005; Shortman
and Naik, 2007). Furthermore, investi-
gation of which DC types are involved
in presentation of pathogen antigens
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PreviewsFigure 1. Presentation of Leishmania Antigen by Monocyte-Derived Dendritic Cells
In the steady state (left panel), lymph nodes contain migratory DCs (green), which constitutively traffic from peripheral tissues, and lymphoid organ-
resident DCs (yellow), which develop within the lymph nodes (Shortman and Naik, 2007; Villadangos and Heath, 2005). Early after L. major infection of
the skin (center panel), migratory DC, and perhaps resident DCs, present L. major antigens to naive T cells. Simultaneously, monocytes (blue) are
recruited to the infection site and also to the lymph node. If the infection persists (right panel), large numbers of monocytes accumulate at both sites,
developing into mo-DCs that eventually become the major DC type presenting L. major antigens and promoting the development of a protective Th1
response.in several models of infection has con-
cluded that only those DC types al-
ready detectable in the steady state
play a role, in some cases capturing
and transporting antigens, in others
presenting antigens transferred from
other DCs, and sometimes doing both
(Villadangos andHeath, 2005). In these
models, no mo-DC appeared to inter-
vene. Could this mean that mo-DCs
only exist in the laboratories of immu-
nologists and that in vivo monocytes
only give rise to macrophages, their
‘‘classical’’ progeny? Not so, accord-
ing to several studies; mo-DCs are a
bona fide component of the DC net-
work (Randolph et al., 1999), but they
only appear ‘‘on demand’’ at sites of in-
flammation (Tacke and Randolph, 2006).
It can take a while for their function to
be relevant, but their intervention can
be crucial, as suggested in the latest
of these studies (Leo´n et al., 2007).
Leo´n et al. (2007) infected the skin of
mice with L. major, a parasite that per-
sists in the dermis for long periods and
causes inflammatory lesions. The au-
thors then carried out a painstakingcharacterization of the DC populations
contained in the infection site, and in
the draining lymph node (LN), at sev-
eral times after infection. They ob-
served a massive influx of monocytes
at both sites from the second week
after L. major inoculation (Figure 1).
These monocytes turned into mo-
DCs in both locations, so Leo´n et al.
(2007) use the terms ‘‘dermal mo-
DCs’’ and ‘‘LN mo-DCs’’ to distinguish
them. They present evidence suggest-
ing that dermal mo-DCs migrate to
the lymph node, where they can be
distinguished from the LN mo-DCs by
their higher expression of maturation
markers (e.g., MHC II, CD40, and
CD86). The most important result of
this study was obtained when the au-
thors used fluorescent parasites, and
antibodies and T cells that recognized
L. major antigens presented on MHC
molecules, to identify those DCs that
were involved in capture and presen-
tation of L. major: Only the mo-DCs
carried out this function; the other DC
types neither contained parasites nor
presented L. major antigens (Figure 1).ImmunIt is easy to imagine how the dermal
mo-DCs could have acquired the par-
asite in the skin, either through capture
or direct infection. It is less clear,
though, how the LN mo-DCs obtained
parasites; they might have captured
them from immigrated dermal mo-
DCs, or the infectious agentmight have
drained or migrated to the lymph
node—ineither case, LNmo-DCsmust
possess a unique property that al-
lowed them, and not other DC types, to
access the parasite.
It is unclear from these studies why
mo-DCs were recruited directly from
the blood to the lymph node. Perhaps
this was a consequence of the skin in-
fection or inflammation spreading via
the lymphatics to the node, but if so,
why did the LN mo-DCs not undergo
the maturation seen for their dermal
counterparts? Furthermore, if both
mo-DC groups were presenting anti-
gens to T cells, was their difference in
maturity of any consequence for the
outcome of the presentation? These
are questions that the study leaves
open for future investigation.ity 26, April 2007 ª2007 Elsevier Inc. 391
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was played by each mo-DC subgroup,
another important observation was
that these DCs produced the cytokine
IL-12, suggesting they played an im-
portant role in inducing T helper 1
(Th1) responses, which are protective
against L. major infection. In support of
this hypothesis, C57Bl/6 mice, which
succumb to the infection, differed from
BALB/c, which are resistant, in that the
number of mo-DCs in the lymph nodes
declined in C57Bl/6 mice after the
fourthweek of infection; this is a finding
not capitulated in BALB/c mice where
numbers continued to increase. A
previous study also showed that
monocyte recruitment was essential
to mount protective Th1 responses
against Toxoplasma infection, al-
though this study did not address
whether the monocytes turned into
DCs (Robben et al., 2005). These stud-
ies suggest a requirement for mo-DC
recruitment for protective immunity
against certain pathogens. This con-
clusion has a parallel in a study of
monocyte differentiation in leprosy pa-
tients: The monocytes of individuals
who developed progressive lesions
only differentiated into macrophages,
whereas containment of the infection
in other patients correlated with the
appearance of mo-DCs in the lepro-
matous lesions, coincident with the in-
duction of a protective Th1 response
(Krutzik et al., 2005). These observa-
tions do not mean that conversion of
monocytes into mo-DCs is always ad-
vantageous; monocytes respond to
certain pathogen signals differentiat-
ing mostly into macrophages rather
than mo-DCs in situations where the
latter might cause more harm than
good (Rotta et al., 2003). The signals
that regulate the differentiation of
monocytes into macrophages or mo-
DCs thus represent important check-392 Immunity 26, April 2007 ª2007 Elsevpoints that may determine which
arm of the immune system—innate or
adaptive—will be preferentially re-
cruited in response to a particular
pathogen. Furthermore, as suggested
in the study by Leo´n et al. (2007), the
decision to differentiate into macro-
phages or mo-DCs may vary over the
course of infection, with the balance
initially biased toward the macro-
phages and later toward DCs.
What position do mo-DCs occupy in
the DC network? The emerging picture
is that the DC types already present in
the steady state are in charge of re-
sponding to the initial challenge (Fig-
ure 1). If the infection is not quickly
contained, ongoing inflammation will
promote the intervention of mo-DCs,
which can thus be seen as an ‘‘emer-
gency’’ population (Shortman and
Naik, 2007; Tacke and Randolph,
2006) (Figure 1). These conclusions
have important implications for the de-
velopment of vaccines and immuno-
therapeutic approaches that attempt
to harness the potential of DCs. Vac-
cine formulations targeted to surface
markers (e.g., Toll-like receptors or
antigen receptors) expressed by mo-
DCs may not find their intended target
in vivo unless the vaccine promotes
monocyte recruitment and differentia-
tion into mo-DCs. With regards to DC
immunotherapy, perhaps one of the
reasons why the outcome of clinical
trials has been disappointing overall
(e.g., see ‘‘Summary Table of Clinical
Trials’’ by D. Hart and colleagues at
http://www.mmri.mater.org.au), is that
most trials have used mo-DCs, and
this may not be the most appropriate
type of DC for this application. Of
course, the limited success of such
approach does not mean that we
should stop studying or employing
mo-DCs. Nevertheless, studies of hu-
man DCs should perhaps be lessier Inc.‘‘mo-DC-centric’’ and expand to con-
sider the potential of those DC types
constitutively present in lymphoid or-
gans. These DC types have been ex-
tensively characterized in the mouse
system, soanobviousobjective should
now be to identify their equivalents in
humans. Because human lymphoid or-
gans are much less accessible than
their mouse counterparts, it would
then be highly desirable to develop
methods to generate human lymphoid
organ DCs from earlier precursors, as
has been described in the mouse sys-
tem (Shortman and Naik, 2007).
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